Atypical fractures: An issue of concern or a myth?

被引：9

作者：

Al-Ashqar, Mohammad ^{[1
]}

Panteli, Michalis ^{[2
]}

Chakrabarty, Gautam ^{[3
]}

Giannoudis, Peter V. ^{[2
]}

机构：

[1] Leeds Gen Infirm, Dept Trauma & Orthopaed, Leeds, W Yorkshire, England

[2] Univ Leeds, Sch Med, Acad Dept Trauma & Orthopaed, Clarendon Wing,Level A,Great George St, Leeds LS1 3EX, W Yorkshire, England

[3] Univ Huddersfield, Dept Trauma & Orthopaed, Huddersfield Royal Infirm, Huddersfield, W Yorkshire, England

来源：

INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED | 2018年 / 49卷 / 03期

关键词：

Atypical; Osteoporosis; Stress/insufficiency fractures; Bisphosphonates; SUBTROCHANTERIC STRESS-FRACTURES; SUPPRESSED BONE TURNOVER; FEMORAL-SHAFT FRACTURES; POSTMENOPAUSAL WOMEN; IN-VITRO; BISPHOSPHONATE USE; SALMON-CALCITONIN; OSTEOPOROSIS; RISK; ALENDRONATE;

D O I：

10.1016/j.injury.2017.12.016

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Atypical Femoral Fractures (AFF) represent fractures located between the lesser trochanter and the supracondylar flare of a femur. An increasing pool of evidence supports their association with the prolonged use of bisphosphonates, even though a direct correlation is yet to be proved. The purpose of this review is to encapsulate the current evidence associating bisphosphonate use and the development of AFFs, the clinical features related to their presentation, as well as to report the armamentarium of strategies available in the prevention and treatment of AFFs. Based on these evidence, we propose a management algorithm for AFFs, that can serve as a guide for patients presenting with this condition. (C) 2018 Elsevier Ltd. All rights reserved.

引用

页码：649 / 655

页数：7

共 80 条

[21] Recent advances in understanding the mechanism of action of bisphosphonates [J].

Coxon, Fraser P. ;

Thompson, Keith ;

Rogers, Michael J. .

CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (03) :307-312

[22] Bone remodelling at a glance [J].

Crockett, Julie C. ;

Rogers, Michael J. ;

Coxon, Fraser P. ;

Hocking, Lynne J. ;

Helfrich, Miep H. .

JOURNAL OF CELL SCIENCE, 2011, 124 (07) :991-998

[23] Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial [J].

Cummings, SR ;

Black, DM ;

Thompson, DE ;

Applegate, WB ;

Barrett-Connor, E ;

Musliner, TA ;

Palermo, L ;

Prineas, R ;

Rubin, SM ;

Scott, JC ;

Vogt, T ;

Wallace, R ;

Yates, AJ ;

LaCroix, AZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (24) :2077-2082

[24] Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis [J].

Cummings, Steven R. ;

San Martin, Javier ;

McClung, Michael R. ;

Siris, Ethel S. ;

Eastell, Richard ;

Reid, Ian R. ;

Delmas, Pierre ;

Zoog, Holly B. ;

Austin, Matt ;

Wang, Andrea ;

Kutilek, Stepan ;

Adami, Silvano ;

Zanchetta, Jose ;

Libanati, Cesar ;

Siddhanti, Suresh ;

Christiansen, Claus .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :756-765

[25]

Dell R, ANN M AM AC ORTH SUR, P7

[26] Incidence of Atypical Nontraumatic Diaphyseal Fractures of the Femur [J].

Dell, Richard M. ;

Adams, Annette L. ;

Greene, Denise F. ;

Funahashi, Tadashi T. ;

Silverman, Stuart L. ;

Eisemon, Eric O. ;

Zhou, Hui ;

Burchette, Raoul J. ;

Ott, Susan M. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (12) :2544-2550

[27] Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases [J].

Delmas, Pierre D. .

JOURNAL OF CLINICAL DENSITOMETRY, 2008, 11 (02) :325-338

[28]

Deng HW, 2005, CURRENT TOPICS IN BONE BIOLOGY, P1, DOI 10.1142/9789812701176

[29] Bisphosphonates: Mechanism of action and role in clinical practice [J].

Drake, Mathew T. ;

Clarke, Bart L. ;

Khosla, Sundeep .

MAYO CLINIC PROCEEDINGS, 2008, 83 (09) :1032-1045

[30]

Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235

← 1 2 3 4 5 6 7 8 →